Enable Accessibility Enable Accessibility


The fight against global infectious diseases is made significantly more achievable through collaboration. Takeda is forging partnerships and collaborating across R&D, clinical science, operations and commercial functions to achieve its mission of making important vaccines available to those who need them.



Collaboration with Frazier Healthcare Partners to launch HilleVax, Inc., a biopharmaceutical company to advance the development and commercialization of norovirus vaccine candidate HIL-214 (formerly TAK-214).1


Japan Ministry of Health Labour & Welfare

Completed multiple subsidy programs for BLB-750 for Japanese pandemic influenza preparedness.

Partnership to rapidly and sustainably supply COVID-19 vaccines in Japan.



Manufacturing and commercializing Novavax’ COVID-19 vaccine (Nuvaxovid) at Hikari facility in Japan during the pandemic and beyond.2



Importing and distributing Moderna’s COVID-19 vaccine (Spikevax) to Japan during the pandemic.3


U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority

Contract to develop TAK-426, a Zika vaccine candidate, for the U.S. with the option to use data generated for filing also in affected regions around the world.4



  1. Takeda Vaccines Newsroom. Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate. July 2021. Retrieved March 11, 2022.
  2. Takeda Vaccines Newsroom. Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan. August 2020. Retrieved March 11, 2022.
  3. Takeda Vaccines Newsroom. Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan. October 2020. Retrieved March 11, 2022.